PDLEX Performance — PGIM Target Date 2060 Fund, Class R2
Data updated: 2026-10-13
PDLEX returned +11.98% year to date and +22.53% over one year to Jul 2026. Annualised returns are +15.97% over 3 years and +9.41% over 5 years. The fund beat its Target-Date category average: $100 invested three years ago grew to $156, against $146 for the category, and to $123 over one year, against $116. Volatility over the past three years was 11.78% a year. In the 12 months to Jul 2026 the fund lost a net $506K, and assets reached $11.42M.
PDLEX Growth of $100
What $100 invested in PGIM Target Date 2060 Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Target-Date category average over the same months.
| Period | PDLEX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $123 | $116 |
| 3 years (Aug 2023 – Jul 2026) | $156 | $146 |
| 5 years (Aug 2021 – Jul 2026) | $157 | $142 |
| Since data start (Aug 2019 – Jul 2026) | $216 | $186 |
PDLEX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +11.98% |
| 1 year | +22.53% |
| 3 years (annualised) | +15.97% |
| 5 years (annualised) | +9.41% |
PDLEX Annual Returns
Calendar-year total returns of PGIM Target Date 2060 Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +11.98% |
| 2025 | +19.29% |
| 2024 | +13.14% |
| 2023 | +18.17% |
| 2022 | −15.69% |
| 2021 | +19.34% |
| 2020 | +11.27% |
| 2019 (Aug–Dec) | +7.96% |
PDLEX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.4% | +2.5% | −6.5% | +8.9% | +3.7% | +0.9% | −0.8% | — | — | — | — | — |
| 2025 | +3.2% | −0.6% | −3.0% | +0.1% | +5.0% | +4.0% | +0.3% | +3.2% | +2.8% | +1.5% | +0.7% | +0.9% |
| 2024 | −0.4% | +3.9% | +3.2% | −3.6% | +4.2% | +0.9% | +2.3% | +2.3% | +2.0% | −2.5% | +3.5% | −3.0% |
| 2023 | +7.3% | −3.1% | +1.6% | +0.9% | −1.8% | +5.8% | +3.5% | −2.6% | −4.1% | −3.1% | +8.3% | +5.3% |
| 2022 | −3.8% | −1.7% | +1.6% | −6.8% | +0.7% | −8.8% | +7.1% | −3.9% | −9.6% | +6.3% | +8.2% | −4.2% |
| 2021 | +0.2% | +3.2% | +3.4% | +4.2% | +1.6% | +0.5% | +0.8% | +2.0% | −3.8% | +4.4% | −2.7% | +4.5% |
| 2020 | −2.0% | −7.9% | −15.0% | +10.4% | +4.9% | +2.9% | +4.4% | +4.8% | −3.0% | −1.5% | +11.1% | +5.0% |
| 2019 | — | — | — | — | — | — | — | −2.4% | +2.4% | +2.4% | +2.4% | +3.1% |
PDLEX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 11.78%
- 3-year Sharpe ratio: 0.97 (vs 4.5% risk-free rate)
- Best month: +8.91% (Apr 2026)
- Worst month: −6.50% (Mar 2026)
PDLEX Fund Flows
Monthly money in and out of PGIM Target Date 2060 Fund, from SEC Form N-PORT.
- 12-month net flow: −$506K
- 12-month gross sales (incl. reinvestments): $4.6M
- Sales ÷ redemptions: 0.90×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $507K | $85K | $422K |
| Jun 2026 | $179K | $49K | $130K |
| May 2026 | $179K | $1.1M | −$956K |
| Apr 2026 | $313K | $982K | −$669K |
| Mar 2026 | $390K | $1.8M | −$1.4M |
| Feb 2026 | $232K | $79K | $153K |
| Jan 2026 | $231K | $277K | −$46K |
| Dec 2025 | $1.9M | $117K | $1.8M |
| Nov 2025 | $157K | $124K | $33K |
| Oct 2025 | $172K | $88K | $84K |
| Sep 2025 | $157K | $117K | $40K |
| Aug 2025 | $216K | $317K | −$102K |
PDLEX Assets Under Management
Net assets of PGIM Target Date 2060 Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $11.42M |
| 2026-04-30 | $11.41M |
| 2026-01-30 | $12.83M |
| 2025-10-31 | $10.99M |
| 2025-07-31 | $10.18M |
| 2025-04-30 | $8.88M |
| 2025-01-31 | $8.77M |
| 2024-10-31 | $8.75M |
| 2024-07-31 | $8.40M |
| 2024-04-30 | $7.17M |
| 2024-01-31 | $6.39M |
| 2023-10-31 | $6.96M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.